Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HSCS
stocks logo

HSCS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
--
--
-1.875
-28.98%
--
--
-1.275
-43.83%
--
--
-1.315
-48.83%
Estimates Revision
The market is revising Upward the revenue expectations for HeartSciences Inc. (HSCS) for FY2026, with the revenue forecasts being adjusted by 2581.58% over the past three months. During the same period, the stock price has changed by -20.72%.
Revenue Estimates for FY2026
Revise Upward
up Image
+2581.58%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-16.21%
In Past 3 Month
Stock Price
Go Down
down Image
-20.72%
In Past 3 Month
Wall Street analysts forecast HSCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSCS is 10.50 USD with a low forecast of 9.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast HSCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSCS is 10.50 USD with a low forecast of 9.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.640
sliders
Low
9.00
Averages
10.50
High
12.00
Current: 2.640
sliders
Low
9.00
Averages
10.50
High
12.00
Ascendiant Capital
Lucas Ward
Strong Buy
Maintains
$15 → $14
2025-03-18
Reason
Ascendiant Capital
Lucas Ward
Price Target
$15 → $14
2025-03-18
Maintains
Strong Buy
Reason
Maxim Group
Allen Klee
Strong Buy
Reiterates
$12
2024-12-18
Reason
Maxim Group
Allen Klee
Price Target
$12
2024-12-18
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for HeartSciences Inc (HSCS.O) is -0.53, compared to its 5-year average forward P/E of -1.20. For a more detailed relative valuation and DCF analysis to assess HeartSciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.20
Current PE
-0.53
Overvalued PE
-0.25
Undervalued PE
-2.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.91
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
-1.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
225.45
Current PS
0.00
Overvalued PS
1224.62
Undervalued PS
-773.72
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

HSCS News & Events

Events Timeline

(ET)
2025-06-04
09:02:30
HeartSciences recesives FDA BDD for Aortic Stenosis ECG algorithm
select
2025-06-03 (ET)
2025-06-03
09:03:11
HeartSciences announces grant by USPTO for ECG assessment of heart function
select
2025-05-29 (ET)
2025-05-29
09:03:11
HeartSciences signs first MyoVista Insights platform customer
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
10-01Benzinga
Ascendiant Capital Reaffirms Buy Rating on HeartSciences, Reduces Price Target to $9

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.

  • Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

[object Object]
Preview
9.5
09-12Newsfilter
HeartSciences Shares Business Update and Announces Financial Results for First Quarter of Fiscal 2026

  • Company Overview: HeartSciences Inc. is an AI-powered medical technology company focused on enhancing ECGs/EKGs for earlier heart disease detection, recently achieving FDA Breakthrough Device Designation and launching the MyoVista Insights software platform.

  • MyoVista Insights Launch: The MyoVista Insights platform modernizes ECG management systems, allowing integration with existing devices and hospital workflows without additional capital expenditures, while also introducing CPT reimbursement codes for AI-ECG algorithms.

  • Financial Performance: For the first quarter of fiscal 2026, HeartSciences reported no significant revenue, with approximately $2.8 million in cash and $3.1 million in shareholders' equity, but has since raised additional funds to strengthen its balance sheet.

  • Future Plans: The company aims to submit its MyoVista wavECG device for FDA approval and expand its intellectual property portfolio, while positioning itself to achieve regulatory clearances and initial revenues in 2026.

[object Object]
Preview
1.0
08-19Globenewswire
Join the Live Stream of Day 1 at the Emerging Growth Conference 85 on August 20; Registration Now Open

  • Emerging Growth Conference Announcement: The 85th Emerging Growth Conference is scheduled for August 20 & 21, 2025, focusing on companies with strong management and growth potential across various sectors.

  • Day 1 Schedule Highlights: Keynote speakers include CEOs from companies such as Immuron Limited, Nutriband, Inc., and Journey Medical Corporation, presenting their innovative products and strategies.

  • Day 2 Schedule Highlights: Presentations will feature executives from Eshallgo, Inc., Grove Collaborative Holdings, Inc., and U.S. Energy Corporation, among others, discussing their business developments.

  • Engagement and Participation: Attendees can register for the conference, submit questions to presenting companies, and access replays via the EmergingGrowth.com platform.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is HeartSciences Inc (HSCS) stock price today?

The current price of HSCS is 2.64 USD — it has increased 3.53 % in the last trading day.

arrow icon

What is HeartSciences Inc (HSCS)'s business?

HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.

arrow icon

What is the price predicton of HSCS Stock?

Wall Street analysts forecast HSCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSCS is 10.50 USD with a low forecast of 9.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is HeartSciences Inc (HSCS)'s revenue for the last quarter?

HeartSciences Inc revenue for the last quarter amounts to 1.90K USD, decreased % YoY.

arrow icon

What is HeartSciences Inc (HSCS)'s earnings per share (EPS) for the last quarter?

HeartSciences Inc. EPS for the last quarter amounts to -1.58 USD, decreased -40.15 % YoY.

arrow icon

What changes have occurred in the market's expectations for HeartSciences Inc (HSCS)'s fundamentals?

The market is revising Upward the revenue expectations for HeartSciences Inc. (HSCS) for FY2026, with the revenue forecasts being adjusted by 2581.58% over the past three months. During the same period, the stock price has changed by -20.72%.
arrow icon

How many employees does HeartSciences Inc (HSCS). have?

HeartSciences Inc (HSCS) has 15 emplpoyees as of December 05 2025.

arrow icon

What is HeartSciences Inc (HSCS) market cap?

Today HSCS has the market capitalization of 7.83M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free